Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant

Clinical Cancer Research

Volumn 2, Issue 4, 1996, Pages 679-686

  McCaffery, Mary ^a   Yao, Tzy Jyun ^a   Linda Williams, ^a   Livingston, Philip O ^a   Houghton, Alan N ^a   Chapman, Paul B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BCG VACCINE; CANCER VACCINE; GANGLIOSIDE GD2; IDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; QS 21; THERACYS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; MALE; MELANOMA; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; FEMALE; GANGLIOSIDES; GENES, MHC CLASS II; HLA-DQ ANTIGENS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MALE; MELANOMA; MIDDLE AGED; MYCOBACTERIUM BOVIS; RABBITS; SURVIVAL RATE;

EID: 0029865646     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Hamilton, W. B., Helling, F., Lloyd, K. O., and Livingston, P. O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer, 53: 566-573, 1993.
2. Cheresh, D. A., Pierschbacher, M. D., Herzig, M. A , and Mujoo, K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix. J. Cell Biol., 102: 688-696, 1986.
3. Chapman, P. B., Lonberg, M., and Houghton, A. N. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship between avidity, effector functions, tumor targeting, and antitumor activity. Cancer Res. 50: 1503-1509, 1990.
4. Dippold, W. G., Knuth, A., and Meyer zum Buschenfelde. K. Inhibition of human melanoma cell growth in vitro by monoclonal antiGD3-ganglioside antibody. Cancer Res. 44: 806-810, 1984.
5. Vadhan-Raj, S., Cordon-Cardo, C., Carswell, E. A., Mintzer, D., Dantis, L., Duteau, C., Templeton, M. A., Oettgen, H. F., Old, L. J., and Houghton, A. N. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J. Clin. Oncol. 6: 1636-1648, 1988.
6. Caulfield, J., Barna, B., Murthy, S., Tubbs, R., Sergi, J., Mendendorp, S., and Bukowski, R. M. Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-α in patients with malignant melanoma. J. Biol. Response Modif. 9: 319-328, 1990.
7. Raymond, J., Kirkwood, J., Vlock, D., Rabkin, M., Day, R., Whiteside, T., Herberman, R., Mascari, R., and Simon, B. A phase Ib trial of murine monoclonal antibody R24 (anti-GD3) in metastatic melanoma. Proc. Am. Soc. Clin. Oncol. 10: 298, 1991.
8. Creekmore, S., Urba, W., Koop, W., Ewel, C., Hecht, T., Smith, I., Janik, J., Steis, R., Fenton, R., Sharfman, W., Conlon, K., Sznol, M., Holmlund, J., Curti, B., Gause, B., Houck, M., Beveridge, J., Jones, M., and Longo, D. Phase IB/II trial of R24 antibody and interleukin-2 (IL2) in melanoma. Proc. Am. Soc. Clin. Oncol. 11: 345, 1992.
9. Tai, T., Cahan, L. D., Tsuchida, T., Saxton, R. E., Irie, R. F., and Morton. D. L. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int. J. Cancer, 35: 607-612, 1985.
10. Livingston, P. O., Ritter, G., Oettgen, H. F., and Old, L. J. Immunization of melanoma patients with purified gangliosides. In: H. F. Oettgen (ed.), Gangliosides and Cancer, pp 293-300. New York: VCH Publishers, 1989.
11. Chapman, P. B., and Houghton, A. N. Induction of IgG antibodies against GD3 in rabbits by an anti-idiotypic monoclonal antibody. J. Clin. Invest. 88: 186-192, 1991.
12. Chapman, P. B., Livingston, P. O., Morrison, M. E., Williams, L., and Houghton, A. N. Immunization of melanoma patients with antiidiotypic monoclonal antibody BEC2 which mimics GD3 ganglioside: pilot trials using no immunological adjuvant. Vaccine Res., 3: 59-69, 1994.
13. Livingston, P. O , Wong, G. Y. C., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Jones Calves, M., Helling, F., Ritter, G., Oettgen, H. F., and Old, L. J. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin Oncol. 12: 1036-1044, 1994.
14. Mittelman, A., Chen, Z. J , Yang, H., Wong, G. Y., and Ferrone, S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA, 89: 466-470, 1992.
15. Kensil, C. R., Patel, U., Lennick, M., and Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J. Immunol. 146: 431-437, 1991.
16. Kensil, C. R., Barrett, C., Kushner, N., Beltz, G., Storey, J., Patel, V., Recchia, J., Aubert, A., and Marciani, D. Development of a genetically engineered vaccine against feline leukemia virus infection. J. Am. Vet. Med. Assoc. 199: 1423-1427, 1991.
17. Wu, J. Y., Gardner, B. H., Murphy, C. I., Seals, J. R., Kensil, C. R., Recchia, J., Beltz, G. A., Newman, G. W., and Newman, M. J. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-I vaccine. J. Immunol., 148: 1519-1525, 1992.
18. Newman, M. J., Wu, J. Y., Coughlin, R. T., Murphy, C. I., Seals, J. R., Wyand, M. S. and Kensil, C. R. Immunogenicity and toxicity testing of an experimental HIV-I vaccine in nonhuman primates. AIDS Res. Hum. Retroviruses, 8: 1413-1418, 1992.
19. White, A. C., Cloutier, P., and Coughlin, R. T. A purified saponin acts as an adjuvant for a T-independent antigen. Adv. Exp. Med. Biol. 303: 207-210, 1991.
20. Livingston, P. O., Adluri, S., Helling, F., Yao, T. J., Kensil, C. R., Newman, M. J., and Marciani, D. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine, 12: 1275-1280, 1994.
21. Kabat, E., Wu, T., Reid-Miller, M., Perry, H., and Gottesmann, K. Sequences of Proteins of Immunological Interest. Washington DC: U. S. Department of Health and Human Services, U. S. Government Printing Office, 1987
22. Ng, J., Hurley, C. K., Baxter-Lowe, L. A., Chopek, M., Coppo, P. A., Hegland, J., Kukuruga, D., Monos, D., Rosner, G., Schmeckpeper, B., Yang, S. Y., Dupont, B., and Hartzman, B. J. Large-scale oligonucleotide typing for HLA-DRB1/3/4 and HLA-DQB1 is highly accurate and reliable. Tissue Antigens. 42: 473-479, 1993
23. Rieger, R., Michaelis. A., and Green, M. M. Glossary of Genetics, Classical and Molecular, Ed. 5. Berlin: Springer-Verlag, 1991.
24. HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference, pp. 1073-1074. Oxford: Oxford University Press, 1992.
25. Livingston, P. O., Adluri, S., Zhang, S , Chapman, P., Raychaudhuri, S., and Merrit, J. A. Impact of immunological adjuvants and administration route on HAMA response after immunization with murine monoclonal antibody MELIMMUNE-1 in melanoma patients. Vaccine Res., 4: 87-94, 1995.
26. Balch, C. M., Soong, S., Shaw, H. M., Urist, M. M., and McCarthy, W. H. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: C. M. Balch, A. N. Houghton, G. W. Milton, A. J. Sober, and S. Soong (eds.), Cutaneous Melanoma, Ed. 2, pp. 165-187. Philadelphia: J. B. Lippincott Co., 1992
27. Drepper, H., Bieb, B., Hofherr, B., Hundeiker, M., Lippold, A., Otto, F., Padberg, G., Peters, A., and Wiebelt, H. The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Horneide, Cancer (Phila.), 71: 1239-1246, 1993.
28. Parkinson, D. R., Houghton, A. N., Hersey, P., and Borden, E. C. Biologic therapy of melanoma. In: C. M. Balch. A. N. Houghton, G. W. Milton, A. J. Sober, and S. Soong (eds.). Cutaneous Melanoma, Ed. 2. pp. 522-541. Philadelphia: J. B. Lippincott Co., 1992.
29. Brocker, E. B., Suter, L., Czarnetzki, B. M., and Macher, E. BCG immunotherapy in stage I melanoma patients. Does it influence prognosis determined by HLA-DR expression in high-risk primary tumors? Cancer Immunol. Immunother., 23: 155-157, 1986.
30. Chapman, P. B., McCaffery, M., Zuklys, K., Giorgio, N., and Houghton, A N. Immunization with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: superiority of the intravenous route. Proc. Am. Assoc. Cancer Res., 36: 493, 1995.
31. Lee, J. E., Reveille, J. D., Ross, M. I., and Platsoucas, C. D HLA-DQBI×0301 association with increased cutaneous melanoma risk. Int. J. Cancer, 59: 510-513, 1994.